Christopher Posner, PRESIDENT AND CEO at Cara Therapeutics, Inc. (CARA), sold 372 shares at $4.72 ($2K) on 2025-02-04, disclosed to the SEC on 2025-02-06.
Scheduled sale ($2k) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| CARA | SELL | 2024-08-02 | $1K | — | Filing → |
| CARA | SELL | 2024-05-06 | $3K | — | Filing → |
| CARA | SELL | 2024-03-04 | $5K | — | Filing → |